Febrile Whole Blood Specimen Collection and Testing
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03498027|
Recruitment Status : Recruiting
First Posted : April 13, 2018
Last Update Posted : October 4, 2018
|Condition or disease||Intervention/treatment|
|Febrile Infection Anthrax||Device: TaqMan Bacillus anthracis Detection Kit|
Whole blood samples will be collected from febrile patients presenting with fever of unknown origin and flu-like syndromes. Collection sites will be advised of collection requirements specific to patient population with the goal of collecting samples form patient between the ages of 2-89 years of age. Samples collected will be de-identified and assigned a specific study number. Study numbers and labels will be provided to collection site by the study monitor. Samples must be shipped to MRIGlobal or designated study site on the day of collection.
Collection sites will consent patients and collect one (1) 4 mL whole blood sample from adults and either (1) 2 mL pediatric whole blood sample or 0.5 mL whole blood sample collected in a micro collection container from pediatric patients (anticoagulant: K2EDTA or defined alternative) from each patient enrolled into the study. Patients may not be enrolled in the study more than once. Patients considered for enrollment will be logged on an enrollment log. Log must be reviewed by the site prior to considering a patient for study enrollment to confirm enrollment status. Samples collected will be de-identified and assigned a specific study number. Study numbers and labels will be provided to collection site by the study monitor.
Study site will accept or reject samples based on shipping verification procedures and then process samples acceptable for testing within 24 hours of receipt. Sample testing must be performed in accordance with the Applied Biosystems™ Bacillus anthracis Detection Kit instructions for use.
At study start, study site will test whole blood samples received from collection sites daily (e.g. Tuesday, Wednesday, Thursday, and Friday) using the Applied Biosystems™ Bacillus anthracis Detection Kit. No reference testing will be required since the study is designed only to demonstrate product specificity. Samples are assumed to be negative for Bacillus anthracis. A minimum of 50, but likely 100 febrile whole blood samples will be tested at MRIGlobal.
Data generated will demonstrate product specificity when testing febrile whole blood samples.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Febrile Whole Blood Specimen Collection and Testing Protocol to Demonstrate Product Specificity for the Applied Biosystems™ Bacillus Anthracis Detection Kit|
|Actual Study Start Date :||July 26, 2018|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||November 2018|
Device: TaqMan Bacillus anthracis Detection Kit
The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
- Product Specificity [ Time Frame: 1 day ]Data generated will demonstrate product specificity when testing whole blood samples.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03498027
|Contact: Barbara Jones, MTfirstname.lastname@example.org|
|United States, Florida|
|Tarpon Springs, Florida, United States, 33319|
|Contact: Angelica Freddo 954-449-6131 email@example.com|
|Principal Investigator: Jean-Claude Labissiere, MD|
|United States, Massachusetts|
|New England Center for Clinical Research||Recruiting|
|Fall River, Massachusetts, United States, 02720|
|Contact: Mark Bergeron 508-672-7450 firstname.lastname@example.org|
|Principal Investigator: Ehab Sorial, MD|
|Medical Research Network||Recruiting|
|Franklin, Massachusetts, United States, 02038|
|Contact: Pura Requintina 503-384-0033 ext 204 email@example.com|
|Principal Investigator: Greg Chiklis, Ph.D.|